Schnieders Capital Management LLC Sells 17,738 Shares of Abbott Laboratories (NYSE:ABT)

Schnieders Capital Management LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 25.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,778 shares of the healthcare product maker’s stock after selling 17,738 shares during the period. Abbott Laboratories accounts for approximately 1.3% of Schnieders Capital Management LLC’s holdings, making the stock its 22nd biggest position. Schnieders Capital Management LLC’s holdings in Abbott Laboratories were worth $5,809,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. International Assets Investment Management LLC lifted its holdings in shares of Abbott Laboratories by 24.4% in the 3rd quarter. International Assets Investment Management LLC now owns 9,543 shares of the healthcare product maker’s stock valued at $912,000 after acquiring an additional 1,874 shares during the last quarter. Wedge Capital Management L L P NC lifted its holdings in shares of Abbott Laboratories by 9.5% in the 3rd quarter. Wedge Capital Management L L P NC now owns 3,413 shares of the healthcare product maker’s stock valued at $331,000 after acquiring an additional 296 shares during the last quarter. Douglas Lane & Associates LLC lifted its holdings in shares of Abbott Laboratories by 4.5% in the 3rd quarter. Douglas Lane & Associates LLC now owns 16,809 shares of the healthcare product maker’s stock valued at $1,628,000 after acquiring an additional 725 shares during the last quarter. 1900 Wealth Management LLC lifted its holdings in shares of Abbott Laboratories by 38.7% in the 3rd quarter. 1900 Wealth Management LLC now owns 5,891 shares of the healthcare product maker’s stock valued at $571,000 after acquiring an additional 1,643 shares during the last quarter. Finally, DAVENPORT & Co LLC lifted its holdings in shares of Abbott Laboratories by 20.5% in the 3rd quarter. DAVENPORT & Co LLC now owns 955,567 shares of the healthcare product maker’s stock valued at $92,825,000 after acquiring an additional 162,877 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Abbott Laboratories news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the completion of the sale, the executive vice president now owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The disclosure for this sale can be found here. Insiders sold a total of 56,435 shares of company stock worth $6,451,298 over the last three months. Corporate insiders own 0.47% of the company’s stock.

Abbott Laboratories Stock Up 0.5 %

ABT stock traded up $0.50 during trading on Tuesday, hitting $107.57. 3,849,265 shares of the company’s stock traded hands, compared to its average volume of 5,728,185. The firm has a market capitalization of $186.65 billion, a P/E ratio of 33.51, a PEG ratio of 2.58 and a beta of 0.74. The business has a fifty day simple moving average of $114.00 and a two-hundred day simple moving average of $107.97. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion for the quarter, compared to analyst estimates of $9.88 billion. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. Abbott Laboratories’s revenue was up 2.2% compared to the same quarter last year. During the same period last year, the company posted $1.03 earnings per share. Sell-side analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.05%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s payout ratio is 68.54%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ABT. Barclays reduced their price objective on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday. Raymond James increased their price objective on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Royal Bank of Canada reduced their price objective on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, April 18th. Citigroup increased their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Evercore ISI increased their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $121.80.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.